These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12458089)

  • 1. Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin.
    Fredenburgh JC; Anderson JA; Weitz JI
    Trends Cardiovasc Med; 2002 Oct; 12(7):281-7. PubMed ID: 12458089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase.
    Anderson JA; Fredenburgh JC; Stafford AR; Guo YS; Hirsh J; Ghazarossian V; Weitz JI
    J Biol Chem; 2001 Mar; 276(13):9755-61. PubMed ID: 11134031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
    Buyue Y; Misenheimer TM; Sheehan JP
    J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism.
    Sheehan JP; Walke EN
    Blood; 2006 May; 107(10):3876-82. PubMed ID: 16672689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin.
    Yuan QP; Walke EN; Sheehan JP
    Biochemistry; 2005 Mar; 44(9):3615-25. PubMed ID: 15736971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antithrombin-based anticoagulants.
    Desai UR
    Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and evaluation a new generation of low molecular weight heparin.
    Zhao D; Sang Q; Cui H
    Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective use of fondaparinux in patient with unresponsiveness to nadroparin.
    Hartinger JM; Svobodová A; Malíková I; Šachl R; Slanař O
    J Clin Pharm Ther; 2021 Apr; 46(2):539-542. PubMed ID: 33277918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa.
    Sheehan JP; Kobbervig CE; Kirkpatrick HM
    Biochemistry; 2003 Sep; 42(38):11316-25. PubMed ID: 14503882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacologic overview of current and emerging anticoagulants.
    Nutescu EA; Shapiro NL; Chevalier A; Amin AN
    Cleve Clin J Med; 2005 Apr; 72 Suppl 1():S2-6. PubMed ID: 15853173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation.
    Bazargani F; Albrektsson A; Yahyapour N; Braide M
    Perit Dial Int; 2005; 25(4):394-404. PubMed ID: 16022098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
    Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
    Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covalent antithrombin-heparin complexes.
    Patel S; Berry LR; Chan AK
    Thromb Res; 2007; 120(2):151-60. PubMed ID: 16978685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists.
    Tripodi A; Primignani M; Braham S; Chantarangkul V; Clerici M; Moia M; Peyvandi F
    Dig Liver Dis; 2016 Oct; 48(10):1208-13. PubMed ID: 27470055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator.
    Barrow RT; Parker ET; Krishnaswamy S; Lollar P
    J Biol Chem; 1994 Oct; 269(43):26796-800. PubMed ID: 7929416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.